Reagents and instruments for immunology, cell biology and molecular biology.

Norepinephrine hydrochloride [329-56-6]

Print

Cat# NB-64-138340-500mg

Size : 500mg

Brand : Neo Biotech

Request more information

Remove All

Norepinephrine hydrochloride

(Synonyms: L-Noradrenaline hydrochloride, Levarterenol hydrochloride) Copy Product Info

Synonyms: L-Noradrenaline hydrochloride, Levarterenol hydrochloride

Catalog No. T60245 Copy Product Info

Purity: 99.98%

Norepinephrine hydrochloride is the hydrochloride salt of the endogenous catecholamine norepinephrine and acts primarily as an α₁ and β₁ adrenergic receptor agonist. In vivo, norepinephrine functions as a neurotransmitter involved in sympathetic nerve signaling, and in vitro, it is used to study adrenergic receptor-related pathways.

Cas No. 329-56-6

Custom-made molecule. TargetMol’s expert synthesis team delivers cost-effective solutions. Contact us for inquiries. Committed to serving you.

For research use only—not for human use. No sales to individuals. Use as intended only.

Select Batch

Purity:99.98%

Appearance:Solid

Color:White

Product Information

Bioactivity

Description	Norepinephrine hydrochloride is the hydrochloride salt of the endogenous catecholamine norepinephrine and acts primarily as an α₁ and β₁ adrenergic receptor agonist. In vivo, norepinephrine functions as a neurotransmitter involved in sympathetic nerve signaling, and in vitro, it is used to study adrenergic receptor-related pathways.
In vitro	Methods: HMC3 cells were co-treated with 50 μM Norepinephrine hydrochloride and LPS for 48 hours, and caspase-3 activity was measured using a colorimetric assay. Results: Norepinephrine hydrochloride significantly reduced the LPS-induced increase in caspase-3 activity. [1]
Synonyms	L-Noradrenaline hydrochloride, Levarterenol hydrochloride
Disease Modeling Protocol	Sepsis-associated cardiomyopathy model Modeling Mechanism： Norepinephrine hydrochloride works synergistically with lipopolysaccharide (LPS) to induce cardiomyopathy through SIRT3/HO-1 axis-mediated ferroptosis: ① NE alone has no significant cardiotoxicity, but it can exacerbate LPS-induced oxidative stress, increasing reactive oxygen species (ROS) and lipid peroxidation levels (4-HNE and MDA are elevated); ② It inhibits SIRT3 activity, relieves its inhibition of p300, promotes HO-1 acetylation and enhances stability, accelerates heme degradation and releases ferrous ions, and induces iron overload; ③ Iron overload and lipid peroxidation together induce cardiomyocyte ferroptosis, accompanied by myocardial hypertrophy and fibrosis, ultimately leading to heart failure. Related Products： Norepinephrine hydrochloride (T60245) Modeling Method： Experimental Subject： Mice, C57BL/6, 8–12 weeks old, Body weight 25–28 g Dosage and Administration Route： ① Core modelling (two-hit protocol): - First challenge: Intraperitoneal (i.p.) injection of LPS at 5 mg/kg, single dose; - Second challenge: Simultaneous LPS administration with subcutaneous implantation of osmotic pump; Norepinephrine at 2 µg/kg/min via continuous infusion for 9 days; ② Control treatment: - LPS-only group: intraperitoneal injection of 5 mg/kg LPS+osmotic pump infusion of physiological saline; - NE-only group: Intraperitoneal injection of physiological saline+osmotic pump infusion of 2 µg/kg/min Norepinephrine; - Blank control: Intraperitoneal injection of saline+osmotic pump infusion of saline; ③ Intervention validation group (optional): - Ferroptosis inhibitor: Ferrostatin-1 (Fer-1), 2 mg/kg/day, intraperitoneal injection, administered concurrently with modelling; - SIRT3 activator: 2-APQC, 30 mg/kg, intraperitoneal injection, administered continuously throughout modelling period Dosing Frequency and Duration Model： First strike: single-dose administration; Secondary challenge: Continuous infusion for 9 days Validation： 1. Pathological Indicators: - Myocardial Injury: HE staining showed cardiomyocyte hypertrophy (cross-sectional area increased by more than 250), and Masson staining showed an increased proportion of interstitial fibrosis area (p<0.01); - Ferroplasmosis Characteristics: Transmission electron microscopy showed mitochondrial shrinkage, DHE staining showed increased ROS levels (fluorescence intensity more than 3 times that of the control group), and significantly increased ferrous ion content in tissues (OD value ≥0.4, p<0.001); 2. Molecular Indicators: - Ferroplasmosis Pathway: Western blot showed upregulated expression of HO-1 and 4-HNE proteins and downregulated expression of SIRT3 (p<0.01); - Myocardial Markers: Serum troponin T (cTnT) and creatine kinase isoenzyme (CK-MB) levels were significantly increased (p<0.001); 3. Functional Indicators: - Cardiac Function: Echocardiography showed that the left ventricular ejection fraction (EF%) decreased to below 60% (control group ≥80%, p<0.01); Survival status: The 9-day survival rate after modeling was more than 30% lower than that of the LPS group alone (p<0.05). Precautions： References：Ma D,et,al. Norepinephrine exacerbates LPS-induced cardiomyopathy via SIRT3/HO-1 axis-mediated ferroptosis. Crit Care. 2025 Aug 13;29(1):354.

Chemical Properties

Molecular Weight	205.64
Formula	C₈H₁₂ClNO₃
Cas No.	329-56-6
Smiles	[C@@H](CN)(O)C1=CC(O)=C(O)C=C1.Cl

Storage & Solubility Information

Storage

Keep away from moisture,Store under nitrogen, Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

H2O: 80 mg/mL (389.03 mM), Sonication is recommended.

DMSO: 40 mg/mL (194.51 mM), Sonication is recommended.

Solution Preparation Table

DMSO/H2O

	1mg	5mg	10mg	50mg
1 mM	4.8629 mL	24.3143 mL	48.6287 mL	243.1434 mL
5 mM	0.9726 mL	4.8629 mL	9.7257 mL	48.6287 mL
10 mM	0.4863 mL	2.4314 mL	4.8629 mL	24.3143 mL
20 mM	0.2431 mL	1.2157 mL	2.4314 mL	12.1572 mL
50 mM	0.0973 mL	0.4863 mL	0.9726 mL	4.8629 mL
100 mM	0.0486 mL	0.2431 mL	0.4863 mL	2.4314 mL

Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO stock solution to 400 µL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 µL Tween 80 and mix well until fully clarified.

3) Add 450 µL Saline,PBS or ddH₂O and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

.label-data{font-weight:bold;min-width:100px;}.label-data,.data{display:inline-block;min-width:100px;}.description table{word-break:break-all;}.description table td{min-width:200px;}